Table 3 Sublingual buprenorphine therapy
From: Patients' perspectives on buprenorphine subcutaneous implant: a case series
Since: | To: | Dosage |
|---|---|---|
2004 | 2008 | bup—8 mg |
2008 | Dose reduction attempted | bup—1mg |
2009 | 2012 | bup—8 mg |
2012 | 2014 | bup + nal—8 mg |
2014 | Dose reduction attempted | bup + nal—6 mg |
2014 | 2016 | bup + nal—12 mg |
2016 | 2017 | bup + nal—8 mg |
2017 | Dose reduction attempted | bup + nal—4 mg |
2018 | 2019 | bup + nal—8 mg |
2019 | 2020 | bup + nal—12 mg |
2020 | 2021 | bup + nal—8 mg |
2021 | 2023 | bup + nal—12 mg |
January 2023 | Dose reduction | bup + nal—8 mg |